Celltrion’s Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical trial for Treating Colorectal Cancer
Celltrion’s Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical trial for Treating Colorectal Cancer
Shots:
• Celltrion has completed Phase I on safety and efficacy of CT-P16 in June 18
• CT-P16 extended to Phase III as planned by submission of application to National Authority of Medicines and Health Products, I.P. (Infarmed) of Portugal
• Celltrion has plan to conduct Phase III clinical trial for CT-P16 in about 150 sites with 20 countries starting with Portugal, Europe, Asia and South America
Click here to read full press release/ article | Ref: Celltrion | Image: Forbes